of complications following Angio-Seal use (2) . The authors claim that a total of 6400 vascular access sites were closed using Angio-Seal at their institution with a complication rate of only 0.32%. The complications they describe include thrombosis at the site of closure, embolization of part of the device and stenosis at the puncture site. Their assessment of the device revealed a small complication rate with a probable "decrease in hospital costs" due to early discharge. A study by Applegate et al. published in 2006 not only compared the use of Angio-Seal versus manual compression, but also the differences between each generation of Angio-Seal devices (3). This study assessed two groups each with 3,898 patients. The trial concluded that Angio-Seal devices were greater than 98% effective in achieving vascular closure, and also that the rates of complications were similar to that of manual compression alone. Limitations of this study include it being a non-randomized retrospective analysis. The follow-up was also only during the admission period. A prospective assessment of Angio-Seal devices was finally published by Aksoy et al. in 2006 (4) . The study had a limited sample of 77 patients, but found that only 2 patients had significant complications (including a hematoma and a pseudoanuerysm). The majority of the patients had a 6 F sheath employed. The study was restricted by its size and its lack of comparative data to manual compression. In 2007, a randomized control trial was published by Upponi et al. on 100 patients (5). This trial found that there was "no significant difference in complications between manual compression and Angio-Seal", but as expected, a decreased hemostatic time. A total of 6 complications were noted in the Angio-Seal group and 7 in the compression group. It should be noted that this trial only assessed for complications up to one week post procedure. It should be stressed that for a significant difference between the two groups a much higher power (i. e., a greater number of participants) would have been required. One of the largest reviews published was in 2007 by Geyik et al. (6) . This group retrospectively reviewed the placement of 1,443 Angio-Seal devices in 1,099 patients. The authors found that a small number of major complications occurred primarily in the group who had an interventional procedure performed. This group also found that the complication rate was higher in patients receiving anticoagulation (especially heparin and an antiplatelet agent). The authors concluded that the rate of complications were low and thus deemed the use of Angio-Seal as safe and effective.
A number of studies have also been performed to assess whether anticoagulation during percutaneous closure increases the risk of complications. One particular study by Exaire et al. concluded that vascular closure devices could be used safely despite "aggressive polypharmacy anticoagulation" (7) . However, the type of anticoagulation is also important. Another study by the same principal investigator found that the use of glycoprotein IIb/IIIa anticoagulants were involved with a two-fold increase in complications (8) . Our pawith minimal disease and those greater than 4 mm in diameter. Complete absorption of the device occurs between 60 and 90 days.
A number of reviews have been performed to assess the Angio-Seal device, all of which have had varying results. One of the first reviews published was that by Abando et al. (1) . The study retrospectively analyzed 188 patients in whom Angio-Seal devices were deployed. The majority of the patients had a 5 F sheath inserted, and were allowed to mobilize between 58 and 219 min. The only complications were a false aneurysm and a vessel occlusion (due to the anchor lifting up an intimal plaque). The authors concluded that the Angio-Seal device was successful in almost all patients and that adverse complications could be avoided by following the manufacturer's guidelines. Goyen et al. presented a number tient was not on this medication. The conclusions of this group are a contradiction to what was later described by Geyik et al. (6) .
A thorough paper was published by Kalapatapu et al. in 2006 which provided advice on techniques for the management of complications of arterial closure devices (9) . In the instance of arterial occlusion, their advice depended upon the site of occlusion. Blockage of the femoral artery at the site of puncture has been described. Their advice is that this will require operative exploration. The authors also described methods of managing embolization of a closure device. They advised that following appropriate investigations to ascertain the level of occlusion, an embolectomy should be performed. This was performed in our case.
It is interesting to hypothesize what may have lead to embolization of the device in our patient. He had healthy vessels despite being a smoker and having diabetes. The use of Angio-Seal in diseased vessels is not advised by the manufacturers, thus making smoking and diabetes a relative contraindication. Given that it was foreign material that had embolized into the patient's distal arteries, it appears almost certain only an embolectomy would have been therapeutic in this patient. One must have an index of suspicion when a patient such as this presents again following a radiological procedure.
It is apparent from our research of the literature that Angio-Seal devices have had limited assessment with well-structured randomized trials that compare it to manual compression. The consensus appears to be that they provide rapid hemostasis with a similar complication rate to manual compression. What we wish to emphasize is that major complications of their use can occur, and must be borne in mind when a patient presents again following an endoluminal procedure.
